These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16675200)

  • 1. Galantamine added to antipsychotic treatment in chronic schizophrenia: cognitive improvement?
    Norén U; Björner A; Sonesson O; Eriksson L
    Schizophr Res; 2006 Jul; 85(1-3):302-4. PubMed ID: 16675200
    [No Abstract]   [Full Text] [Related]  

  • 2. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia.
    Dyer MA; Freudenreich O; Culhane MA; Pachas GN; Deckersbach T; Murphy E; Goff DC; Evins AE
    Schizophr Res; 2008 Jul; 102(1-3):88-95. PubMed ID: 18325740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of galantamine added to clozapine on cognition of five patients with schizophrenia.
    Bora E; Veznedaroğlu B; Kayahan B
    Clin Neuropharmacol; 2005; 28(3):139-41. PubMed ID: 15965314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation.
    Sharma T; Reed C; Aasen I; Kumari V
    Schizophr Res; 2006 Jul; 85(1-3):73-83. PubMed ID: 16797163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galantamine for treatment-resistant schizophrenia.
    Allen TB; McEvoy JP
    Am J Psychiatry; 2002 Jul; 159(7):1244-5. PubMed ID: 12091212
    [No Abstract]   [Full Text] [Related]  

  • 6. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
    Lee SW; Lee JG; Lee BJ; Kim YH
    Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galantamine for the treatment of cognitive impairments in people with schizophrenia.
    Buchanan RW; Conley RR; Dickinson D; Ball MP; Feldman S; Gold JM; McMahon RP
    Am J Psychiatry; 2008 Jan; 165(1):82-9. PubMed ID: 17986678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
    Lindenmayer JP; Khan A
    Schizophr Res; 2011 Feb; 125(2-3):267-77. PubMed ID: 20850275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease.
    Rockwood K; Fay S; Gorman M
    Int J Geriatr Psychiatry; 2010 Feb; 25(2):191-201. PubMed ID: 19548273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia.
    Rosse RB; Deutsch SI
    Clin Neuropharmacol; 2002; 25(5):272-5. PubMed ID: 12410061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversible Pisa syndrome (pleurothotonus) due to the cholinesterase inhibitor galantamine: case report.
    Cossu G; Melis M; Melis G; Maccioni E; Putzu V; Catte O; Putzu PF
    Mov Disord; 2004 Oct; 19(10):1243-4. PubMed ID: 15389998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant galantamine for cognitive dysfunction in a patient with bipolar disorder.
    Dias VV; Brissos S; Gorman JM
    J Psychiatr Pract; 2006 Sep; 12(5):327-31. PubMed ID: 16998423
    [No Abstract]   [Full Text] [Related]  

  • 13. Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naïve patients with schizophrenia.
    Hill SK; Schuepbach D; Herbener ES; Keshavan MS; Sweeney JA
    Schizophr Res; 2004 May; 68(1):49-63. PubMed ID: 15037339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant galantamine to risperidone improves negative and cognitive symptoms in a patient presenting with schizophrenialike psychosis after traumatic brain injury.
    Bennouna M; Greene VB; Defranoux L
    J Clin Psychopharmacol; 2005 Oct; 25(5):505-7. PubMed ID: 16160637
    [No Abstract]   [Full Text] [Related]  

  • 15. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Heinrichs RW
    Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
    [No Abstract]   [Full Text] [Related]  

  • 16. Galantamine improves cognition in schizophrenic patients stabilized on risperidone.
    Schubert MH; Young KA; Hicks PB
    Biol Psychiatry; 2006 Sep; 60(6):530-3. PubMed ID: 16806095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alleviation of multiple abnormalities by galantamine treatment in two patients with dementia with Lewy bodies.
    Holm AC
    Am J Alzheimers Dis Other Demen; 2004; 19(4):215-8. PubMed ID: 15359558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlates of cognitive deficits in first episode schizophrenia.
    Heydebrand G; Weiser M; Rabinowitz J; Hoff AL; DeLisi LE; Csernansky JG
    Schizophr Res; 2004 May; 68(1):1-9. PubMed ID: 15037334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
    Lee BJ; Lee JG; Kim YH
    J Psychopharmacol; 2007 Jun; 21(4):421-7. PubMed ID: 17092979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive deficits as treatment targets in schizophrenia.
    Gold JM
    Schizophr Res; 2004 Dec; 72(1):21-8. PubMed ID: 15531404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.